标题
Management of bone disease in multiple myeloma
作者
关键词
-
出版物
Expert Review of Hematology
Volume 7, Issue 1, Pages 113-125
出版商
Informa UK Limited
发表日期
2014-01-17
DOI
10.1586/17474086.2013.874943
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
- (2013) Rakesh Bam et al. AMERICAN JOURNAL OF HEMATOLOGY
- Dickkopf-1 is a key regulator of myeloma bone disease: Opportunities and challenges for therapeutic intervention
- (2013) Fuling Zhou et al. BLOOD REVIEWS
- Cellular Mechanisms of Multiple Myeloma Bone Disease
- (2013) Angela Oranger et al. Clinical & Developmental Immunology
- Critical Role of AKT Protein in Myeloma-induced Osteoclast Formation and Osteolysis
- (2013) Huiling Cao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease
- (2013) Evangelos Terpos et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy
- (2013) T Scullen et al. LEUKEMIA
- Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways
- (2013) F Bruzzese et al. Cell Death & Disease
- Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy
- (2012) E. Terpos et al. ANNALS OF ONCOLOGY
- Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial
- (2012) G. J. Morgan et al. BLOOD
- Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
- (2012) Allan Lipton et al. EUROPEAN JOURNAL OF CANCER
- High Circulating Sclerostin is Present in Patients with Thalassemia-associated Osteoporosis and Correlates with Bone Mineral Density
- (2012) E. Voskaridou et al. HORMONE AND METABOLIC RESEARCH
- Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients
- (2011) Maurizio Zangari et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma
- (2011) Michel Delforge et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy
- (2011) Evangelos Terpos et al. INTERNATIONAL JOURNAL OF CANCER
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
- (2011) David H. Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial
- (2011) James Berenson et al. LANCET ONCOLOGY
- A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function
- (2011) S Vallet et al. LEUKEMIA
- Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study
- (2011) Giovanni D'arena et al. LEUKEMIA & LYMPHOMA
- Efficacy and safety of medical ozone (O3) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I–II study
- (2011) Carla Ida Ripamonti et al. ORAL ONCOLOGY
- Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide
- (2011) S. A. Polyzos et al. OSTEOPOROSIS INTERNATIONAL
- Impact of Radiotherapy on Pain Relief and Recalcification in Plasma Cell Neoplasms
- (2011) Mario Balducci et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid
- (2010) E. Terpos et al. ANNALS OF ONCOLOGY
- Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration
- (2010) J. Moreaux et al. BLOOD
- Sclerostin: Current Knowledge and Future Perspectives
- (2010) M. J. C. Moester et al. CALCIFIED TISSUE INTERNATIONAL
- Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis*
- (2010) Thomas Lund et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo
- (2010) Andrew D Chantry et al. JOURNAL OF BONE AND MINERAL RESEARCH
- First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
- (2010) Gareth J Morgan et al. LANCET
- Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial
- (2010) Peter Gimsing et al. LANCET ONCOLOGY
- The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group
- (2010) E Terpos et al. LEUKEMIA
- Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
- (2010) S. Vallet et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma
- (2009) Ravi Vij et al. AMERICAN JOURNAL OF HEMATOLOGY
- The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
- (2009) E. Terpos et al. ANNALS OF ONCOLOGY
- Is VIII worse than IX?
- (2009) M. Makris BLOOD
- Familial multiple myeloma
- (2009) H. T. Lynch et al. BLOOD
- Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
- (2009) M. Fulciniti et al. BLOOD
- Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates
- (2009) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma
- (2009) M Roussou et al. LEUKEMIA
- Pathogenesis and management of myeloma bone disease
- (2009) Dimitrios Christoulas et al. Expert Review of Hematology
- Vertebroplasty in Multiple Myeloma: Outcomes in a Large Patient Series
- (2008) R.J. McDonald et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid
- (2008) M. A. Dimopoulos et al. ANNALS OF ONCOLOGY
- Prevalence and significance of vitamin D deficiency in multiple myeloma patients
- (2008) Ashraf Badros et al. BRITISH JOURNAL OF HAEMATOLOGY
- A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
- (2008) Pellegrino Musto et al. CANCER
- Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma
- (2008) Deborah J Heath et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study of ACE-011 (ActRIIA-IgG1) in Postmenopausal Women*
- (2008) Jon Ruckle et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL*
- (2008) Paul J Kostenuik et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma
- (2008) Ashraf Badros et al. JOURNAL OF CLINICAL ONCOLOGY
- The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
- (2008) E Terpos et al. LEUKEMIA
- Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
- (2008) I Breitkreutz et al. LEUKEMIA
- Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates
- (2008) Vittorio Montefusco et al. LEUKEMIA & LYMPHOMA
- Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions
- (2008) P. Boissy et al. LEUKEMIA RESEARCH
- Vertebroplasty and kyphoplasty are associated with an increased risk of secondary vertebral compression fractures: a population-based cohort study
- (2008) A. S. Mudano et al. OSTEOPOROSIS INTERNATIONAL
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started